Synektik S.A.
ISIN: PLSNKTK00019 | Ticker: SNT | LEI: 259400U0O19JWLVHQN14
Country: Poland
We have become the exclusive distributor for Poland, the Czech Republic and Slovakia of innovative da Vinci robotic systems, used to perform surgical procedures, e.g. in the field of urology, gynecology and general surgery.
We are a national leader in the production and distribution of radiopharmaceuticals for positron emission tomography (PET/CT), used in oncology, cardiology and neurological diagnostics.
The Group has its own IT solutions for archiving, distribution, presentation and processing of radiological images and administrative data. The proprietary project of the Zbadani.pl teleradiology platform offers a number of innovative e-services for medical facilities, doctors and patients. In addition, the Group offers classic IT solutions dedicated to radiology.
2001
Served areaEurope
HeadquartersJózefa Piusa Dziekońskiego 3, 00-728 Warszawa – Poland
| Line item in (pln) | 01.10.2020 | 01.10.2021 | 01.10.2022 |
|---|---|---|---|
| Assets | N/A | 159,685,491.68 | 236,480,185.50 |
| Noncurrent Assets | N/A | 95,741,762.19 | 126,727,126.92 |
| Property Plant And Equipment | N/A | 45,562,376.33 | 35,126,703.51 |
| Intangible Assets Other Than Goodwill | N/A | 28,569,090.34 | 56,632,459.80 |
| Investment Accounted For Using Equity Method | N/A | 661,023.06 | 1,404,895.83 |
| Noncurrent Receivables | N/A | 26,500.00 | 60,587.68 |
| Deferred Tax Assets | N/A | 8,082,900.96 | 13,614,214.98 |
| Noncurrent Loans And Receivables | N/A | 1,670,014.57 | 0.00 |
| Other Noncurrent Nonfinancial Assets | N/A | 37,281.18 | 123,134.15 |
| Noncurrent Finance Lease Receivables | N/A | 3,128,700.58 | 0.00 |
| Current Assets | N/A | 63,943,729.49 | 109,753,058.58 |
| Trade And Other Current Receivables | N/A | 39,312,806.04 | 47,370,342.03 |
| Current Tax Assets Current | N/A | 0.00 | 243,244.00 |
| Other Current Financial Assets | N/A | 0.00 | 1,178,308.70 |
| Current Loans And Receivables | N/A | 1,648,880.00 | 1,704,880.00 |
| Other Current Nonfinancial Assets | N/A | 856,890.03 | 1,297,304.42 |
| Cash and cash equivalents | 10,868,001.71 | 18,270,397.11 | 9,678,540.38 |
| Current Finance Lease Receivables | N/A | 1,015,905.00 | 0.00 |
| Equity And Liabilities | N/A | 159,685,491.68 | 236,480,185.50 |
| Equity | 75,995,309.59 | 80,558,688.71 | 87,846,089.59 |
| Issued Capital | N/A | 4,264,564.50 | 4,264,564.50 |
| Retained Earnings Profit Loss For Reporting Period | N/A | 8,383,810.88 | 10,301,206.37 |
| Retained Earnings Excluding Profit Loss For Reporting Period | N/A | 3,224,840.51 | 7,770,543.35 |
| Statutory Reserve | N/A | 64,663,407.88 | 64,663,407.88 |
| Capital Reserve | N/A | 22,064.94 | 56,007.16 |
| Equity Attributable To Owners Of Parent | N/A | 80,558,688.71 | 87,846,089.59 |
| Liabilities | N/A | 79,126,802.97 | 148,634,095.91 |
| Noncurrent Liabilities | N/A | 24,092,528.95 | 43,726,519.76 |
| Noncurrent Provisions For Employee Benefits | N/A | 124,807.56 | 84,315.51 |
| Noncurrent Payables | N/A | 282,275.28 | 11,771,204.31 |
| Deferred Tax Liabilities | N/A | 1,038,752.42 | 7,599,202.75 |
| Other Noncurrent Nonfinancial Liabilities | N/A | 10,938,843.37 | 11,060,474.85 |
| Longterm Borrowings | N/A | 4,007,099.05 | 1,300,000.00 |
| Current Liabilities | N/A | 55,034,274.02 | 104,907,576.15 |
| Current Provisions For Employee Benefits | N/A | 711,725.01 | 1,040,841.50 |
| Other Shortterm Provisions | N/A | 84,617.00 | 84,617.00 |
| Trade And Other Current Payables | N/A | 44,444,553.09 | 71,592,904.07 |
| Current Tax Liabilities Current | N/A | 689,204.00 | 1,069,802.98 |
| Other Current Nonfinancial Liabilities | N/A | 2,644,165.05 | 7,449,173.63 |
| Line item in (pln) | 01.10.2020/ 01.10.2021 |
01.10.2021/ 01.10.2022 |
|---|---|---|
| Revenue | 128,627,450.41 | 166,860,941.08 |
| Revenue From Sale Of Goods | 33,286,969.72 | 44,386,432.35 |
| Cost Of Merchandise Sold | 75,174,681.40 | 90,688,112.03 |
| Profit Loss From Operating Activities | 11,187,178.07 | 17,617,898.29 |
| Finance Income | 123,116.98 | 1,328,409.51 |
| Finance Costs | 982,368.25 | 5,168,758.87 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | -106,515.09 | -1,488,627.24 |
| Profit Loss Before Tax | 10,221,411.71 | 12,288,921.69 |
| Income Tax Expense Continuing Operations | 1,837,600.83 | 1,987,715.32 |
| Profit Loss From Continuing Operations | 8,383,810.88 | 10,301,206.37 |
| Profit (loss) | 8,383,810.88 | 10,301,206.37 |
| Profit Loss Attributable To Owners Of Parent | 8,383,810.88 | 10,301,206.37 |
| Line item in (pln) | 01.10.2020 | 01.10.2021 | 01.10.2022 |
|---|---|---|---|
| Profit (loss) | N/A | 8,383,810.88 | 10,301,206.37 |
| Adjustments For Reconcile Profit Loss | N/A | 11,488,890.38 | -18,472,703.54 |
| Adjustments For Decrease Increase In Inventories | N/A | 3,195,444.55 | -45,441,587.75 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 7,974,841.90 | 12,039,471.72 |
| Adjustments For Provisions | N/A | 159,387.81 | 330,528.42 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 0.00 | 790,360.33 |
| Other Adjustments For Which Cash Effects Are Investing Or Financing Cash Flow | N/A | 30,524.31 | -212,592.18 |
| Other Adjustments To Reconcile Profit Loss | N/A | -56,498.76 | -1,021,899.26 |
| Adjustments For Reconcile Profit Loss | N/A | 11,488,890.38 | -18,472,703.54 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 2,325,354.00 | 2,207,085.92 |
| Cash Flows From Used In Operating Activities | N/A | 21,710,302.09 | -6,183,781.85 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 3,430,170.62 | 10,221,565.91 |
| Proceeds From Government Grants Classified As Investing Activities | N/A | 240,770.45 | 1,191,397.48 |
| Cash Advances And Loans Made To Other Parties Classified As Investing Activities | N/A | 1,863,500.00 | 1,196,201.56 |
| Cash Receipts From Repayment Of Advances And Loans Made To Other Parties Classified As Investing Activities | N/A | 1,596,200.00 | 666,001.56 |
| Interest Received Classified As Investing Activities | N/A | 155,008.32 | 6,812.01 |
| Cash Flows From Used In Investing Activities | N/A | -3,234,459.37 | -4,550,631.23 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 0.00 | 22,977,290.72 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 2,664,251.00 | 8,681,354.73 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 3,980,586.60 | 6,986,577.94 |
| Dividends Paid Classified As Financing Activities | N/A | 3,838,108.05 | 3,838,108.05 |
| Interest Paid Classified As Financing Activities | N/A | 590,501.67 | 1,328,693.65 |
| Cash Flows From Used In Financing Activities | N/A | -11,073,447.32 | 2,142,556.35 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 7,402,395.40 | -8,591,856.73 |
| Cash and cash equivalents | 10,868,001.71 | 18,270,397.11 | 9,678,540.38 |
Please note that some sums might not add up.
PLSNKTK00019
LEI259400U0O19JWLVHQN14
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.